Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics    SIGHT   FR0013183985

GENSIGHT BIOLOGICS

(SIGHT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
3.56(c) 3.395(c) 3.44(c) 3.365(c) 3.19 Last
267 930 420 934 289 038 127 732 344 168 Volume
-5.07% -4.63% +1.33% -2.18% -5.20% Change
More quotes
Financials (EUR)
Sales 2019 7,10 M
EBIT 2019 -27,7 M
Net income 2019 -27,7 M
Finance 2019 4,59 M
Yield 2019 -
Sales 2020 8,00 M
EBIT 2020 -25,3 M
Net income 2020 -25,4 M
Debt 2020 13,9 M
Yield 2020 -
P/E ratio 2019 -3,49x
P/E ratio 2020 -3,82x
EV / Sales2019 14,8x
EV / Sales2020 15,5x
Capitalization 110 M
More Financials
Company
GenSight Biologics specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2018, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber... 
More about the company
Surperformance© ratings of GenSight Biologics
Trading Rating : Investor Rating : -
More Ratings
Latest news on GENSIGHT BIOLOGICS
01/21GENSIGHT BIOLOGICS : Reports Its Cash Position as of December 31, 2019 and Provi..
BU
01/21GENSIGHT BIOLOGICS : 4th quarter earnings
CO
01/20GENSIGHT BIOLOGICS : Announces its 2020 Financial Calendar
BU
01/16GENSIGHT BIOLOGICS : annual sales release
2019GENSIGHT BIOLOGICS : Announces the Filing of its 2018 Universal Registration Doc..
AQ
2019GENSIGHT BIOLOGICS : obtains EUR15 million in financing through a bond issuance ..
AQ
2019GENSIGHT BIOLOGICS : Announces the Filing of its 2018 Universal Registration Doc..
BU
2019GENSIGHT BIOLOGICS : Obtains €15 Million in Financing Through a Bond Issuance fr..
BU
2019GENSIGHT BIOLOGICS : reports findings from REALITY study and REVERSE-RESCUE anal..
AQ
2019GENSIGHT BIOLOGICS : The Quinze-Vingts Hospital and GenSight Biologics announce ..
AQ
2019GENSIGHT BIOLOGICS : Corporate presentation, November 2019
PU
2019GENSIGHT BIOLOGICS : 3rd quarter earnings
CO
2019GENSIGHT BIOLOGICS : Corporate presentation, October 2019
PU
2019GENSIGHT BIOLOGICS : to present new GS010 data at the 2019 Annual Meeting of the..
PU
2019GENSIGHT BIOLOGICS : integrates the Enternext® PEA-PME 150 index by Euronext
PU
More news
News in other languages on GENSIGHT BIOLOGICS
01/21EN DIRECT DES MARCHES : LVMH, Air France KLM, PSA, Carrefour, Nicox, Logitech..
01/21BIOTECH TIME : point trésorerie pour Nicox, Gensight et Oncodesign, levée de fon..
01/21Les valeurs à suivre mardi 21 janvier 2020 à Paris -
01/21GENSIGHT BIOLOGICS : peut faire face à ses obligations jusqu'à la fin du mois de..
01/21GENSIGHT BIOLOGICS : publie sa situation nette de trésorerie au 31 décembre 2019..
More news
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart GENSIGHT BIOLOGICS
Duration : Period :
GenSight Biologics Technical Analysis Chart | SIGHT | FR0013183985 | MarketScreener
Technical analysis trends GENSIGHT BIOLOGICS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 7,50  €
Last Close Price 3,37  €
Spread / Highest target 167%
Spread / Average Target 123%
Spread / Lowest Target 78,3%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS35.41%119
GILEAD SCIENCES3.65%84 765
VERTEX PHARMACEUTICALS11.94%63 547
REGENERON PHARMACEUTICALS6.75%43 450
WUXI APPTEC CO., LTD.20.50%25 998
GENMAB14.61%15 962